Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions for ...
Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...
Bio-Rad is an established Fortune 1000 biotech company that creates products that help people live longer, healthier lives. Bio-Rad’s Digital Biology Group (DBG) in Pleasanton makes products ...
Choosing the right quality control (QC) system for your laboratory is essential. Not only is it required by worldwide regulations and standards such as the International Organization of ...
Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...
Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I ...
Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results